

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Mon Oct 01 11:17:12 EDT 2007

=====

Application No: 10576042 Version No: 1.0

Input Set:

Output Set:

Started: 2007-09-19 14:38:25.351
Finished: 2007-09-19 14:38:26.674
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 323 ms
Total Warnings: 16
Total Errors: 0
No. of SeqIDs Defined: 16
Actual SeqID Count: 16

| Error code | Error Description |
|------------|---|
| W 213 | Artificial or Unknown found in <213> in SEQ ID (1) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (2) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (3) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (4) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (5) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (6) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (7) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (8) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (9) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (10) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (11) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (12) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (13) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (14) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (15) |
| W 213 | Artificial or Unknown found in <213> in SEQ ID (16) |

SEQUENCE LISTING

<110> Cavanagh, Heather
Sheales, Leath

<120> Compound and Method of Treatment

<130> 801948-0006

<140> 10576042

<141> 2007-09-19

<150> PCT/AU04/01430

<151> 2004-10-18

<150> AU 2003905718

<151> 2003-10-17

<160> 16

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 1

Ala Ile Lys Leu Val Gln Ser Pro

1 5

<210> 2

<211> 15

<212> PRT

<213> Artificial

<220>

<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 2

Ala Ile Lys Leu Val Gln Ser Pro Asn Gly Asn Phe Ala Ala Ser

1 5 10 15

<210> 3

<211> 30

<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 3

Ala Ile Lys Leu Val Gln Ser Pro Asn Gly Asn Phe Ala Ala Ser Phe
1 5 10 15

Val Leu Asp Gly Thr Lys Trp Ile Phe Lys Ser Lys Tyr Tyr
20 25 30

<210> 4
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 4

Ala Ile Lys Leu Val Gln Ser Pro Asp Gly Asp Phe Ala Ala Ser
1 5 10 15

<210> 5
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa can be selected from Ala, Leu or Val

<400> 5

Xaa Ile Lys Leu Val Gln Ser Pro
1 5

<210> 6

<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa can be selected from Leu, Ile, Pro, or Val.

<400> 6

Ala Xaa Lys Leu Val Gln Ser Pro
1 5

<210> 7
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa can be selected from Lys, Pro, Asn, Gln, or His.

<400> 7

Ala Ile Xaa Leu Val Gln Ser Pro
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (4)..(4)

<223> Xaa can be selected from Leu, Ile, or Val.

<400> 8

Ala Ile Lys Xaa Val Gln Ser Pro

1 5

<210> 9

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa can be selected from Leu, Ile, or Val.

<400> 9

Ala Ile Lys Leu Xaa Gln Ser Pro

1 5

<210> 10

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa can be selected from Gln, Asn, His, or Lys.

<400> 10

Ala Ile Lys Leu Val Xaa Ser Pro

1 5

<210> 11

<211> 8

<212> PRT

<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa can be selected from Ser or Thr.

<400> 11

Ala Ile Lys Leu Val Gln Xaa Pro
1 5

<210> 12
<211> 24
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 12

gcuaaucaaac ugguucaguc cccg

24

<210> 13
<211> 45
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 13

gcuaaucaaac ugguucaguc cccgaacggu aacuuucgcug cuucc

45

<210> 14
<211> 90
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 14
gcuaucaaac ugguucaguc cccgaacggu aacuucgcug cuuccuucgu ucuggacggu 60

accaaaugga ucuucaaauuc caaaauacuac 90

<210> 15

<211> 24

<212> RNA

<213> Unknown

<220>

<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 15

gcaauuaagc ucguacaauc ucca 24

<210> 16

<211> 24

<212> DNA

<213> Unknown

<220>

<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 16

cgatagtttg accaagtca gggc 24